In Friday's Analysts' Actions a trio of upgrades for Allergan, Barrick and CST Brands. Allergan (AGN) was upgraded at Leerink to 'Outperform from 'Market Perform.' The firm says "risk/reward is compelling following a significant pullback in the stock" and has a $184 dollar price target for the stock, that's about a 21% upside from where the stock is currently trading. Barrick Gold (ABX) was upgraded to "Conviction Buy" from "Buy" at Goldman Sachs. The price target is $22 a share. Goldman says it see "improving operational profile and growth in copper production" as positives for Barrick Gold. Credit Suisse upgraded CST Brands (CST) to a 'Neutral' form 'Underperform' and also raised its price target to $35 from $29' a share. The firm sees a 'higher retail valuation multiple.' TheStreet's Susannah Lee reports from the NYSE.